

High-Resolution NMR Spectroscopy of a GPCR in Aligned Bicelles

Sang Ho Park,[†] Stefan Prytulla,[‡] Anna A. De Angelis,[†] Jonathan Miles Brown,[§] Hans Kiefer,[‡] and Stanley J. Opella*[†]

Department of Chemistry and Biochemistry, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093-0307, ProSpect Pharma Inc., 9108A Guilford Road, Columbia, Maryland 21046, and m-phasys GmbH, Vor dem Kreuzberg 17, Tübingen 72070, Germany

Received February 8, 2006; E-mail: sopella@ucsd.edu

G protein-coupled receptors (GPCRs) are prized targets for structure determination; however, with seven transmembrane helices and more than 300 residues, they are also among the most challenging. Strategically located in the membrane, these proteins regulate the physiological functions of cells in response to external chemical signals. The information is transmitted through the membrane by a change in conformation, and the resulting activation of a cognate G protein triggers myriad signaling pathways in the cytosol. About 1000 GPCRs have been identified in the human genome. Although most are for sensory functions, several hundred are potential drug receptors.

The structure of only one GPCR has been determined, and that is of rhodopsin,¹ which responds to photons and not chemical ligands. Although efforts are being made to model GPCRs on the structure of rhodopsin and with other computational methods,² it is essential to determine their individual three-dimensional structures in order to understand their mechanisms of action and for structure-based drug design. A number of NMR studies of rhodopsin have been reported that illustrate the complexities encountered in applying both solution NMR to micelle³ and magic angle spinning solid-state NMR to bilayer^{3a,4} samples of polytopic membrane proteins. NMR studies of other GPCRs have been limited to polypeptides corresponding to portions of the proteins,⁵ isolated following low-temperature expression of a GPCR gene in bacteria,⁶ or bound ligands.⁷

Our approach is to refold GPCRs expressed in bacteria as fusion proteins that form inclusion bodies.⁸ By growing the bacteria in an optimized media formulation,⁹ it is possible to obtain tens of milligrams of protein from each liter of culture without scrambling or loss of the isotopic labels. The purified GPCR is reconstituted into DMPC phospholipid vesicles, followed by the addition of short chain phospholipids (DHPC). The resulting bicelles provide a fully hydrated bilayer environment that both immobilizes and aligns the proteins for solid-state NMR experiments.¹⁰ The line narrowing essential for high resolution results from the averaging effects of radio frequency irradiations rather than molecular motions. In aligned samples, the protein structure is mapped directly onto the spectra, and the resonance frequencies provide orientation constraints as input for structure calculations.

Chemokines are small cytokines that control many biological and pathological processes, from immunosurveillance to inflammation, and from viral infection to cancer. The first chemokine receptors to be cloned were CXCR1¹¹ (Figure 1) and CXCR2,¹² the two receptors for interleukin 8 (IL-8), following the finding of specific high-affinity binding of IL-8 to polymorphonuclear leukocytes.¹³ The chemokine CXC ligand IL-8 and related agonists (GRO α , neutrophil activating peptide 2, NAP-2) recruit and activate




Figure 1. The amino acid sequence of CXCR1 arranged to show the transmembrane helices, loops, and terminal regions predicted by a hydrophathy plot.²³ The locations of the isoleucine residues are marked.




Figure 2. (A) Solid-state NMR spectrum of uniformly ¹⁵N-labeled CXCR1 in magnetically aligned bicelles. (B) Two-dimensional PISEMA spectrum of a ¹⁵N Ile-labeled sample. The spectral slice through 3.4 kHz is aligned along the top of the spectrum. The spectra were obtained at 750 MHz on 150 μ L samples with protein concentrations of 0.6 mM. The mix time was 1 ms; the acquisition time was 5 ms during which SPINAL-modulated ¹H decoupling was applied,²⁴ and the recycle delay was 6 s. The data were processed with 100 Hz of exponential line broadening applied in t_2 followed by Fourier transformation. Maximum entropy reconstruction was applied to the full data set in t_1 with no other apodization.²⁵

PMN by binding CXCR1 and CXCR2. As a result, IL-8 and related molecules have been implicated in a wide range of inflammatory disease states characterized by PMN infiltration in organs. Anti-chemokine strategies include antibodies, N-terminal-modified chemokines, and small molecule antagonists. No small molecule inhibitors of CXCR1 are in an advanced clinical stage with the exception of repertaxin, an allosteric inhibitor of CXCR1 and CXCR2.¹⁴ Thus, any structural information that sheds light on either IL-8 antagonists or small molecule ligands of chemokine receptors that do not bind to the “classical” GPCR sites would be extremely valuable.

The solid-state NMR spectrum of uniformly ¹⁵N-labeled CXCR1 in magnetically aligned bicelles is presented in Figure 2A. Significantly, there is only a small amount of signal intensity discernible at the isotropic frequency (\sim 120 ppm), which indicates that nearly all residues are structured and immobilized along with the rest of the protein in the phospholipid bilayers. However, even with carefully optimized cross-polarization conditions, it is possible that signals from some sites are missing due to the effects of

[†] University of California, San Diego.

[§] ProSpect Pharma Inc.

[‡] m-phasys GmbH.

motional averaging. Also, there is no evidence of residual “powder pattern” intensity, which demonstrates that this 350-residue GPCR undergoes rotational diffusion rapidly enough ($D_{\parallel} \geq 10^5 \text{ s}^{-1}$) to perform the averaging necessary to obtain single line resonances from bilayer samples with their normals perpendicular to the magnetic field.^{10,15}

PISEMA (Polarization Inversion Spin Exchange at the Magic Angle)¹⁶ yields high-resolution separated local field spectra, where each resonance from a ¹⁵N-labeled amide site in the protein backbone is characterized by orientation-dependent heteronuclear ¹H–¹⁵N dipolar coupling and ¹⁵N chemical shift frequencies. Helices result in characteristic PISA (Polarity Index Slant Angle)¹⁷ wheel patterns of resonances that reflect their tilt and polarity in the bilayers. The magnitudes of the chemical shift and dipolar coupling frequencies enable atomic-resolution structures of the proteins to be calculated.¹⁸

Figure 2B is a PISEMA spectrum of selectively ¹⁵N Ile-labeled CXCR1 in bicelles. As indicated in Figure 1, more than half of the Ile residues are in transmembrane helices with the others in interhelical loop or terminal regions. A blue circle denotes the PISA wheel portion (70–110 ppm) of the spectrum that contains the resonances from residues in the transmembrane helices; there are nine signals in this region, two of which appear to be more intense than the others. It is reassuring to observe the wheel-like pattern from helical residues; however, because these signals are from residues in six different helices, it is not possible to determine helix tilt or polarity by inspection. Resonances from residues in loop and terminal regions that are likely to have irregular structures have chemical shifts in the 100–140 ppm range (outlined in red); there are about five signals that we would regard as reliable in this region. Signals with apparent dipolar couplings less than about 500 Hz may be artifacts due to mismatch of the ¹H and ¹⁵N radio frequency fields. Consistent with the one-dimensional spectrum in Figure 2, there is little or no intensity near the isotropic frequency that could be ascribed to mobile Ile residues. The spectral slice in Figure 2B includes the weakest signal (102 ppm, 3.4 kHz) in the transmembrane helical region of the spectrum.

The spectrum in Figure 2B is an early result and can be improved upon through further optimization of the sample conditions. Also, many aspects of the instrumentation and methods for experiments on aligned samples of proteins are under development and will contribute to higher resolution and sensitivity in the future. In particular, the implementation of triple-resonance and three-dimensional experiments should enable the resolution and assignment of individual resonances from uniformly labeled samples.¹⁹ The spectrum in Figure 2B demonstrates the complementary use of selective isotopic labeling, which is particularly valuable in this context because the mapping of secondary structure onto the experimental spectra assists the assignment and structure determination processes.²⁰ The ability to obtain spectra with single-site resolution, such as those in Figure 2B, means that GPCRs in phospholipid bilayers are suitable samples for structure determination by solid-state NMR. Moreover, it is possible to utilize these spectra for screening of small molecule libraries and the application of SAR by solid-state NMR^{21,22} for the development of drugs that target GPCRs.

Acknowledgment. This research was supported by Amgen, Inc., and the NIH through Grant RO1GM066978, and a postdoctoral fellowship to A.A.D. (F32GM065833). It utilized the Biomedical Technology Resource for NMR Molecular Imaging of Proteins supported by Grant P41EB002031.

Supporting Information Available: Sample information. This material is available free of charge via the Internet at <http://pubs.acs.org>.

References

- (1) Palczewski, K.; Kumasaka, T.; Hori, T.; Behnke, C. A.; Motoshima, H.; Fox, B. A.; Le Trong, I.; Teller, D. C.; Okada, T.; Stenkamp, R. E.; Yamamoto, M.; Miyano, M. *Science* **2000**, *289*, 739–745.
- (2) (a) Becker, O. M.; Shacham, S.; Marantz, Y.; Noiman, S. *Curr. Opin. Drug Discovery Dev.* **2003**, *6*, 353–361. (b) Trabaino, R. J.; Hall, S. E.; Vaidehi, N.; Floriano, W. B.; Kam, V. W.; Goddard, W. A., III. *Biophys. J.* **2004**, *86*, 1904–1921.
- (3) (a) Getmanova, E.; Patel, A. B.; Klein-Seetharaman, J.; Loewen, M. C.; Reeves, P. J.; Friedman, N.; Sheves, M.; Smith, S. O.; Khorana, H. G. *Biochemistry* **2004**, *43*, 1126–1133. (b) Klein-Seetharaman, J.; Getmanova, E. V.; Loewen, M. C.; Reeves, P. J.; Khorana, H. G. *Proc. Natl. Acad. Sci. U.S.A.* **1999**, *96*, 13744–13749. (c) Klein-Seetharaman, J.; Reeves, P. J.; Loewen, M. C.; Getmanova, E. V.; Chung, J.; Schwalbe, H.; Wright, P. E.; Khorana, H. G. *Proc. Natl. Acad. Sci. U.S.A.* **2002**, *99*, 3452–3457. (d) Klein-Seetharaman, J.; Yanamala, N. V.; Javeed, F.; Reeves, P. J.; Getmanova, E. V.; Loewen, M. C.; Schwalbe, H.; Khorana, H. G. *Proc. Natl. Acad. Sci. U.S.A.* **2004**, *101*, 3409–3413. (e) Loewen, M. C.; Klein-Seetharaman, J.; Getmanova, E. V.; Reeves, P. J.; Schwalbe, H.; Khorana, H. G. *Proc. Natl. Acad. Sci. U.S.A.* **2001**, *98*, 4888–4892.
- (4) (a) Crocker, E.; Patel, A. B.; Eilers, M.; Jayaraman, S.; Getmanova, E.; Reeves, P. J.; Ziliox, M.; Khorana, H. G.; Sheves, M.; Smith, S. O. *J. Biomol. NMR* **2004**, *29*, 11–20. (b) Eilers, M.; Reeves, P. J.; Ying, W.; Khorana, H. G.; Smith, S. O. *Proc. Natl. Acad. Sci. U.S.A.* **1999**, *96*, 487–492. (c) Patel, A. B.; Crocker, E.; Reeves, P. J.; Getmanova, E. V.; Eilers, M.; Khorana, H. G.; Smith, S. O. *J. Mol. Biol.* **2005**, *347*, 803–812. (d) Patel, A. B.; Crocker, E.; Eilers, M.; Hirshfeld, A.; Sheves, M.; Smith, S. O. *Proc. Natl. Acad. Sci. U.S.A.* **2004**, *101*, 10048–10053. (e) Anderson, L. L.; Marshall, G. R.; Crocker, E.; Smith, S. O.; Baranski, T. J. *J. Biol. Chem.* **2005**, *280*, 31019–31026.
- (5) (a) Zheng, H.; Zhao, J.; Wang, S.; Lin, C. M.; Chen, T.; Jones, D. H.; Ma, C.; Opella, S.; Xie, X. Q. *J. Pept. Res.* **2005**, *65*, 450–458. (b) Katragadda, M.; Maciejewski, M. W.; Yeagle, P. L. *Biochim. Biophys. Acta* **2004**, *1663*, 74–81. (c) Geng, L.; Wu, J.; So, S. P.; Huang, G.; Ruan, K. H. *Arch. Biochem. Biophys.* **2004**, *423*, 253–265. (d) Estephan, R.; Englander, J.; Arshava, B.; Samples, K. L.; Becker, J. M.; Naider, F. *Biochemistry* **2005**, *44*, 11795–11810. (e) Choi, G.; Guo, J.; Makryiannis, A. *Biochim. Biophys. Acta* **2005**, *1668*, 1–9.
- (6) Tian, C.; Breyer, R. M.; Kim, H. J.; Karra, M. D.; Friedman, D. B.; Karpay, A.; Sanders, C. R. *J. Am. Chem. Soc.* **2005**, *127*, 8010–8011; **2006**, *128*, 5300.
- (7) (a) Luca, S.; White, J. F.; Sohal, A. K.; Filippov, D. V.; von Boom, J. H.; Grissamer, R.; Baldus, M. *Proc. Natl. Acad. Sci. U.S.A.* **2003**, *100*, 10706–10711. (b) Koenig, B. W.; Kontaxis, G.; Mitchell, D. C.; Louis, J. M.; Litman, B. J.; Bax, A. *J. Mol. Biol.* **2002**, *323*, 441–461.
- (8) (a) Kiefer, H.; Maier, K.; Vogel, R. *Biochem. Soc. Trans.* **1999**, *27*, 908–912. (b) Kiefer, H.; Vogel, R.; Maier, K. *Receptors Channels* **2000**, *7*, 109–119. (c) PCT Patent WO 01/14407, 2000.
- (9) Giesen, A. W.; Bae, L. C.; Barrett, C. L.; Chyba, J. A.; Chaykovsky, M. M.; Cheng, M. C.; Murray, J. H.; Oliver, E. J.; Sullivan, S. M.; Brown, J. M.; Dahlquist, F. W.; Homans, S. W. *J. Biomol. NMR* **2001**, *19*, 255–260.
- (10) De Angelis, A. A.; Nevzorov, A. A.; Park, S. H.; Howell, S. C.; Mrse, A. A.; Opella, S. J. *J. Am. Chem. Soc.* **2004**, *126*, 15340–15341.
- (11) Holmes, W. E.; Lee, J.; Kuang, W. J.; Rice, G. C.; Wood, W. I. *Science* **1991**, *253*, 1278–1280.
- (12) Murphy, P. M.; Tiffany, H. L. *Science* **1991**, *253*, 1280–1283.
- (13) (a) Grob, P. M.; David, E.; Warren, T. C.; DeLeon, R. P.; Farina, P. R.; Homon, C. A. *J. Biol. Chem.* **1990**, *265*, 8311–8316. (b) Samanta, A. K.; Oppenheim, J. J.; Matsushima, K. *J. Exp. Med.* **1989**, *169*, 1185–1189.
- (14) Bertini, R.; Allegretti, M.; Cinzia Bizzarri, C.; Alessio Moriconi, A.; Massimo Locati, M.; Giuseppe Zampella, G.; Maria N. Cervellera, M. N.; Vito Di Cioccio, V.; Cesta, M. C.; Galliera, E.; Martinez, F. O.; Di Bitondo, R.; Troiani, G.; Sabbatini, V.; D’Anniballe, G.; Anacardio, R.; Cutrin, J. C.; Cavalieri, B.; Mainiero, F.; Strippoli, R.; Villa, P.; Di Girolamo, M.; Martin, F.; Gentile, M.; Santoni, A.; Corda, D.; Poli, G.; Mantovani, A.; Ghezzi, P.; Colotta, F. *Proc. Natl. Acad. Sci. U.S.A.* **2004**, *101*, 11791–11796.
- (15) Nevzorov, A. A.; Opella, S. J. *Handbook of Modern Magnetic Resonance*; Kluwer Academic: New York, 2005; pp 1–10.
- (16) Wu, C. H.; Ramamoorthy, A.; Opella, S. J. *J. Magn. Reson.* **1994**, *A109*, 270–272.
- (17) (a) Marassi, F. M.; Opella, S. J. *J. Magn. Reson.* **2000**, *144*, 150–155. (b) Wang, J.; Denny, J.; Tian, C.; Kim, S.; Mo, Y.; Kovacs, F.; Song, Z.; Nishimura, K.; Gan, Z.; Fu, R.; Quine, J. R.; Cross, T. A. *J. Magn. Reson.* **2000**, *144*, 162–167.
- (18) Nevzorov, A. A.; Opella, S. J. *J. Magn. Reson.* **2003**, *160*, 33–39.
- (19) Vosegaard, T.; Nielsen, N. C. *J. Biomol. NMR* **2002**, *225*–247.
- (20) Kamihira, M.; Vosegaard, T.; Mason, A. J.; Straus, S. K.; Nielsen, N. C.; Watts, A. *J. Struct. Biol.* **2005**, *149*, 7–16.
- (21) Shuker, S. B.; Hajduk, P. J.; Meadows, R. P.; Fesik, S. W. *Science* **1996**, *274*, 1531–1534.
- (22) Watts, A. *Nat. Rev. Drug Discovery* **2005**, *4*, 555–568.
- (23) Skranbanek, L.; Campagne, F.; Weinstein, H. *Nucleic Acids Res.* **2003**, *31*, 3856–3858.
- (24) Sinha, N.; Grant, C. V.; Wu, C. H.; De Angelis, A. A.; Howell, S. C.; Opella, S. J. *J. Magn. Reson.* **2005**, *177*, 197–202.
- (25) Jones, D. H.; Opella, S. J. *J. Magn. Reson.* **2006**, *178*, 91–99.

JA0606632